Search

Our Expectations

We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.

Two new claims for Nexgard range in EU and Australia

Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.

Award: Boehringer Ingelheim is Global Top Employer 2022

Global Top Employer 2022

Boehringer unveils first global sustainability publication

Boehringer Ingelheim unveils its first global sustainability publication ‘Imagine’

What we do

Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio

Why cancer care is personal for us

At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.

2019 performance

Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.

Boehringer acquires T3 Pharma

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

opening-solids-launch-fabrik

Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.

2021 PRRS Research Award winners announced

The 2021 European PRRS Research Award winners announced

Partnering pet therapeutics

Learn more about our research focus and our most recent partnerships regarding pet therapeutics.

Generalized pustular psoriasis: The Impact Beyond The Skin

An article on how the symptoms of generalized pustular psoriasis (GPP) are more than just physical, affecting both mental and emotional health

Kicking off 2024 with five new R&D partnerships

We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.

Health for all: How can we contribute to inclusive access?

What drives us to improve the health of humans and animals worldwide

Blue internal teat sealant now in dairy mastitis portfolio

Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio

Partnership to Develop Urea Cycle Disorders Therapy

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

FRONTLINE® becomes Brand of the Year 2021-22

FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards

Bridging the gap in Generalized Pustular Psoriasis (GPP)

Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, discusses published insights from GPP patients.

SENVELGO Best New Product Companion Animals award

SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award